Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

Gary Hogge: Hi, Madison. So we’ve worked with a group in Michigan and a number of other groups. There are a number of well known models and outcome assessments. And so the intention is not to develop something de novo, but to utilize that as far as precedent. And so we’re working with those groups to figure out the best models for that. But we’re not reinventing the wheel here. And as Brian alluded to, the tech transfer is on target at this point. That’s about all we can say.

Unidentified Analyst: Got it. I appreciate it, guys.

Operator: There are no further questions at this time. That concludes our meeting for today. You may now disconnect from the conference.

Brian Culley: Thank you, Jordan. Goodbye, everyone.